IDEAYA Biosciences (IDYA)
(Delayed Data from NSDQ)
$24.27 USD
-0.08 (-0.33%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $24.26 -0.01 (-0.04%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
IDEAYA Biosciences, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
IDYA 24.27 -0.08(-0.33%)
Will IDYA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IDYA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IDYA
Down -8.63% in 4 Weeks, Here's Why You Should You Buy the Dip in IDEAYA Biosciences (IDYA)
IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss
IDYA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Lags Revenue Estimates
All You Need to Know About IDEAYA Biosciences (IDYA) Rating Upgrade to Buy
Wall Street Analysts Predict an 81.88% Upside in IDEAYA Biosciences (IDYA): Here's What You Should Know
Other News for IDYA
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | IDYA ...
IDEAYA Biosciences (IDYA) Price Target Raised by JP Morgan | IDYA Stock News
JPMorgan Raises Price Target for Ideaya Biosciences (IDYA) Amid Growth Potential
JPMorgan ups Ideaya target, adds to Analyst Focus List
IDEAYA Biosciences Announces Key Presentation at ESMO 2025 for Phase 2 Trial in Uveal Melanoma ...